Gene-environment interactions in parkinson's disease: The importance of animal modeling

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 4, 2010, Pages 467-474

  Horowitz, M P ^a,b   Greenamyre, J T ^a,b  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALPHA SYNUCLEIN; DJ 1 PROTEIN; LEUCINE RICH REPEAT KINASE 2; PARKIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN PINK1; UNCLASSIFIED DRUG;

AGE; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL FACTOR; GENE INTERACTION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; LIFESTYLE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEX DIFFERENCE; ANIMAL; DISEASE MODEL; ENVIRONMENT; GENETIC PREDISPOSITION; GENETICS; HEALTH BEHAVIOR; MUTATION; RISK FACTOR;

AGE FACTORS; ANIMALS; DISEASE MODELS, ANIMAL; ENVIRONMENT; ENVIRONMENTAL EXPOSURE; GENETIC PREDISPOSITION TO DISEASE; HEALTH BEHAVIOR; HUMANS; MUTATION; PARKINSON DISEASE; RISK FACTORS; SEX FACTORS;

EID: 77957020116     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.138     Document Type: Review

References (55)

1. Lesage, S. & Brice, A. Parkinsons disease: from monogenic forms to genetic susceptibility factors. Hum. Mol. Genet. 18, R48-R59 (2009).
2. Hardy, J., Lewis, P., Revesz, T., Lees, A. & Paisan-Ruiz, C. The genetics of Parkinsons syndromes: a critical review. Curr. Opin. Genet. Dev. 19, 254-265 (2009).
3. Polymeropoulos, M.H. et al. Mutation in the alpha-synuclein gene identified in families with Parkinsons disease. Science 276, 2045-2047 (1997).
4. Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R. & Goedert, M. Alpha-synuclein in Lewy bodies. Nature 388, 839-840 (1997).
5. Lundvig, D., Lindersson, E. & Jensen, P.H. Pathogenic effects of alpha-synuclein aggregation. Brain Res. Mol. Brain Res. 134, 3-17 (2005).
6. Singleton, A.B. et al. alpha-Synuclein locus triplication causes Parkinsons disease. Science 302, 841 (2003).
7. Miller, D.W. et al. Alpha-synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication. Neurology 62, 1835-1838 (2004).
8. Ross, O.A. et al. Genomic investigation of alpha-synuclein multiplication and parkinsonism. Ann. Neurol. 63, 743-750 (2008).
9. Gründemann, J., Schlaudraff, F., Haeckel, O. & Liss, B. Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinsons disease. Nucleic Acids Res. 36, e38 (2008).
10. C hiba-Falek, O. & Nussbaum, R.L. Effect of allelic variation at the NACP-Rep1 repeat upstream of the alpha-synuclein gene (SNCA) on transcription in a cell culture luciferase reporter system. Hum. Mol. Genet. 10, 3101-3109 (2001).
11. Feany, M.B. & Bender, W.W. A Drosophila model of Parkinsons disease. Nature 404, 394-398 (2000).
12. Zimprich, A. et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607 (2004).
13. Paisán-Ruíz, C. et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinsons disease. Neuron 44, 595-600 (2004).
14. Healy, D.G. et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinsons disease: a case-control study. Lancet Neurol. 7, 583-590 (2008).
15. West, A.B. et al. Parkinsons disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. USA 102, 16842-16847 (2005).
16. Li, Y. et al. Mutant LRRK2(R1441G) BAC transgenic mice recapitulate cardinal features of Parkinsons disease. Nat. Neurosci. 12, 826-828 (2009).
17. Kitada, T. et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 392, 605-608 (1998). (Pubitemid 28207717)
18. Narendra, D., Tanaka, A., Suen, D.F. & Youle, R.J. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J. Cell Biol. 183, 795-803 (2008).
19. Valente, E.M. et al. Hereditary early-onset Parkinsons disease caused by mutations in PINK1. Science 304, 1158-1160 (2004).
20. Park, J. et al. Mitochondrial dysfunction in Drosophila PINK1 mutants is complemented by parkin. Nature 441, 1157-1161 (2006).
21. C lark, I.E. et al. Drosophila pink1 is required for mitochondrial function and interacts genetically with parkin. Nature 441, 1162-1166 (2006).
22. Narendra, D.P. et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol. 8, e1000298 (2010).
23. Bonifati, V. et al. Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism. Science 299, 256-259 (2003). (Pubitemid 36131051)
24. Canet-Avilés, R.M. et al. The Parkinsons disease protein DJ-1 is neuroprotective due to cysteine-sulfinic acid-driven mitochondrial localization. Proc. Natl. Acad. Sci. USA 101, 9103-9108 (2004).
25. Quik, M., OLeary, K. & Tanner, C.M. Nicotine and Parkinsons disease: implications for therapy. Mov. Disord. 23, 1641-1652 (2008).
26. Ascherio, A. et al. Prospective study of caffeine consumption and risk of Parkinsons disease in men and women. Ann. Neurol. 50, 56-63 (2001).
27. T anner, C.M. Advances in environmental epidemiology. Mov. Disord. 25 (suppl. 1), S58-S62 (2010).
28. Weisskopf, M.G., OReilly, E., Chen, H., Schwarzschild, M.A. & Ascherio, A. Plasma urate and risk of Parkinsons disease. Am. J. Epidemiol. 166, 561-567 (2007).
29. Langston, J.W., Ballard, P., Tetrud, J.W. & Irwin, I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219, 979-980 (1983).
30. Ritz, B. & Yu, F. Parkinsons disease mortality and pesticide exposure in California 1984-1994. Int. J. Epidemiol. 29, 323-329 (2000).
31. Priyadarshi, A., Khuder, S.A., Schaub, E.A. & Shrivastava, S. A meta-analysis of Parkinsons disease and exposure to pesticides. Neurotoxicology 21, 435-440 (2000).
32. Costello, S., Cockburn, M., Bronstein, J., Zhang, X. & Ritz, B. Parkinsons disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am. J. Epidemiol. 169, 919-926 (2009).
33. Kamel, F. et al. Pesticide exposure and self-reported Parkinsons disease in the agricultural health study. Am. J. Epidemiol. 165, 364-374 (2007).
34. Betarbet, R., Sherer, T.B., MacKenzie, G., Garcia-Osuna, M., Panov, A.V. & Greenamyre, J.T. Chronic systemic pesticide exposure reproduces features of Parkinsons disease. Nat. Neurosci. 3, 1301-1306 (2000).
35. Greenamyre, J.T., Cannon, J.R., Drolet, R. & Mastroberardino, P.G. Lessons from the rotenone model of Parkinsons disease. Trends Pharmacol. Sci. 31, 141-142; author reply 142 (2010).
36. Manning-Bog, A.B., McCormack, A.L., Li, J., Uversky, V.N., Fink, A.L. & Di Monte, D.A. The herbicide paraquat causes up-regulation and aggregation of alpha-synuclein in mice: paraquat and o-synuclein. J. Biol. Chem. 277, 1641-1644 (2002).
37. Gash, D.M. et al. Trichloroethylene: Parkinsonism and complex 1 mitochondrial neurotoxicity. Ann. Neurol. 63, 184-192 (2008).
38. Rathke-Hartlieb, S. et al. Sensitivity to MPTP is not increased in Parkinsons disease-associated mutant alpha-synuclein transgenic mice. J. Neurochem. 77, 1181-1184 (2001).
39. Nieto, M. et al. Increased sensitivity to MPTP in human alpha-synuclein A30P transgenic mice. Neurobiol. Aging 27, 848-856 (2006).
40. Pérez-Sánchez, F. et al. Prosurvival effect of human wild-type alpha-synuclein on MPTP-induced toxicity to central but not peripheral catecholaminergic neurons isolated from transgenic mice. Neuroscience 167, 261-276 (2010).
41. Song, D.D., Shults, C.W., Sisk, A., Rockenstein, E. & Masliah, E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp. Neurol. 186, 158-172 (2004).
42. Norris, E.H., Uryu, K., Leight, S., Giasson, B.I., Trojanowski, J.Q. & Lee, V.M. Pesticide exposure exacerbates P-synucleinopathy in an A53T transgenic mouse model. Am. J. Pathol. 170, 658-666 (2007).
43. Manning-Bog, A.B., McCormack, A.L., Purisai, M.G., Bolin, L.M. & Di Monte, D.A. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J. Neurosci. 23, 3095-3099 (2003).
44. Fernagut, P.O. et al. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 61, 991-1001 (2007).
45. Venderova, K. et al. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinsons disease. Hum. Mol. Genet. 18, 4390-4404 (2009).
46. Ng, C.H. et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J. Neurosci. 29, 11257-11262 (2009).
47. Saha, S. et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 29, 9210-9218 (2009).
48. Palacino, J.J. et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J. Biol. Chem. 279, 18614-18622 (2004).
49. C asarejos, M.J., Menéndez, J., Solano, R.M., Rodríguez- Navarro, J.A., García de Yébenes, J. & Mena, M.A. Susceptibility to rotenone is increased in neurons from parkin null mice and is reduced by minocycline. J. Neurochem. 97, 934-946 (2006).
50. Wang, C. et al. Drosophila overexpressing parkin R275W mutant exhibits dopaminergic neuron degeneration and mitochondrial abnormalities. J. Neurosci. 27, 8563-8570 (2007).
51. Kitada, T. et al. Impaired dopamine release and synaptic plasticity in the striatum of PINK1-deficient mice. Proc. Natl. Acad. Sci. USA 104, 11441-11446 (2007).
52. Haque, M.E. et al. Cytoplasmic Pink1 activity protects neurons from dopaminergic neurotoxin MPTP. Proc. Natl. Acad. Sci. USA 105, 1716-1721 (2008).
53. Meulener, M. et al. Drosophila DJ-1 mutants are selectively sensitive to environmental toxins associated with Parkinsons disease. Curr. Biol. 15, 1572-1577 (2005).
54. Kim, R.H. et al. Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl- 1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc. Natl. Acad. Sci. USA 102, 5215-5220 (2005).
55. Manning-Bog, A.B. et al. Increased vulnerability of nigrostriatal terminals in DJ-1-deficient mice is mediated by the dopamine transporter. Neurobiol. Dis. 27, 141-150 (2007).